BUZZ-GEO shares rise due to $950 million sale of ICE facilities and expanded stock buyback plan

Reuters, October 5 – U.S. biotechnology company Alector announced on Monday that Swiss pharmaceutical giant Roche will pay up to 1.27 billion dollars to obtain licensing rights for its experimental Parkinson's disease therapy. Boosted by this news, Alector’s shares surged 72% in pre-market trading. Genentech, a subsidiary of Roche, will pay Alector a 100 million dollar upfront payment, with an additional payment of up to 1.17 billion dollars if the therapy meets certain developmental, regulatory, and sales milestones. Alector will also receive royalty payments. Specific details are as follows: the agreement grants Genentech exclusive global rights to develop, produce, and commercialize AL050, an experimental therapy targeting enzyme deficiency associated with Parkinson’s disease. Genentech will be responsible for the development, regulatory filings, production, and commercialization of the therapy. AL050 is an enzyme replacement therapy designed to address GCase enzyme deficiency—which leads to the buildup of certain fats and increases the risk of Parkinson’s. This deal is the latest in a series of licensing agreements Roche has reached to expand its drug development pipeline. In June, Roche and Nurix Therapeutics entered into a licensing and collaboration agreement involving a blood cancer medication, with a deal value of up to 2.3 billion dollars.

08:10 AM EDT, 10/05/2026 (MT Newswires) -- Harrow (HROW) said Monday that it has closed its earlier stated acquisition of Tyrvaya from Viatris (VTRS), acquiring worldwide rights to the nasal spray, except for Japan. Harrow said that, in accordance with the terms reported in August, the company paid $30 million in cash at closing and may pay up to $70 million in sales-based milestones. Tyrvaya is an FDA-approved nasal spray for dry eye disease, Harrow said. Harrow said it expects the product to generate more than $30 million in revenue next year.

08:10 AM EDT, 10/05/2026 (MT Newswires) -- Ecarx (ECX) said Monday that it has closed its acquisition of the entire Flyme software business portfolio, including the Flyme Auto in-vehicle cockpit operating system and a cross-device Flyme operating system. The company said it paid 1.8 billion Chinese renminbi ($266 million) in cash, about 70% of which was funded by syndicated bank loans from Chinese commercial banks and roughly 30% from internal sources. After closing, Ecarx said it will provide the acquired business with 200 million renminbi to support its operations. Shares of Ecarx were up 5.8% pre-bell Monday.

Search string for querying individual stock trends in the workspace: STXBZ "Today's Outlook" newsletter: https://refini.tv/3LI4BU7 "Morning News Brief" newsletter: https://refini.tv/3dKUyB8 Reuters, October 5 - On Monday, U.S. stock index futures edged lower as tech stocks retreated after reaching record highs. As Treasury yields and oil prices remain elevated, investors are seeking new clues about the direction of monetary policy. .N ** RXO RXO.N: Market focus — RXO shares rose following C.H. Robinson's announcement of a 5.8 billions USD acquisition plan nL6N45R0N4 ** Harley-Davidson HOG.N: Market focus — Citi upgraded Harley-Davidson to "Buy," shares climbed nL6N45R0M3 ** GEO Group GEO.N: Spotlight — GEO gained as it sold ICE facilities for 950 millions USD and expanded its stock buyback nL6N45R0MR ** Vistra VST.N: Spotlight — Vistra rallied as it was reportedly set to receive a 4.2 billions USD U.S. nuclear loan nL4N45R0L8 ** Vaxcyte PCVX.O: Spotlight — Vaxcyte surged after positive late-stage clinical trial data for its pneumococcal vaccine nL4N45R0K0 ** Estée Lauder EL.N: Spotlight — Barclays upgraded Estée Lauder to "Overweight," shares advanced nL6N45R0HX ** PTC PTC.O: Spotlight — Schneider Electric agreed to acquire PTC for 22.6 billions USD, shares jumped nL6N45R0HV (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automatic translation may contain errors or fail to convey the required context, Reuters does not guarantee the accuracy of automatically translated texts and provides them solely for readers’ convenience. Reuters accepts no liability for any damages or losses arising from the use of automated translation features.)